INTRODUCTION
Vascular endothelial growth factor (VEGF-A), which exists in humans in multiple isoforms (1) , is a proangiogenic ligand that is upregulated in a large proportion of primary malignancies (2) . Tumor expression levels of VEGF-A have been correlated with vascularization, pathological stage, metastasis, and poor outcome in patients with metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), and metastatic renal cell carcinoma (mRCC) (3) (4) (5) (6) (7) (8) (9) (10) . In addition, circulating VEGF-A levels are elevated in a proportion of patients with carcinomas, and some reports have suggested an association between circulating VEGF-A levels and patient outcomes (11) .
The monoclonal antibody bevacizumab, which selectively inhibits VEGF-A signaling, has been extensively examined across multiple tumor types in both combination and single-agent trials. Phase III studies have demonstrated that the addition of bevacizumab to standard chemotherapy regimens significantly improves progressionfree survival (PFS) and overall survival (OS) in patients with mCRC and advanced nonsquamous NSCLC (12) (13) (14) . Treatment containing bevacizumab in previously untreated mRCC has also been associated with significant improvements in PFS compared with immunotherapy alone (15, 16) . Positive data from clinical trials of multitargeted agents that also inhibit VEGF-A signaling-such as the tyrosine kinase inhibitors sunitinib (17) and sorafenib (18) Nevertheless, no known association exists between the survival benefit and the response rate to bevacizumab-containing therapy in mCRC (19, 20) , demonstrating the need for biomarkers to better identify those who will derive the greatest incremental benefit. Biomarker analyses suggest that bevacizumab-containing therapy confers clinical benefit irrespective of the status of k-ras, b-raf, p53 (21) (22) (23) , and thrombospondin-2 (24) . Clinical outcome with targeted agents may be influenced by the expression level of the target (e.g., trastuzumab and human epidermal growth factor receptor 2; ref. 25 ). Therefore, VEGF-A is a strong candidate for predicting the survival benefit associated with bevacizumab treatment. Tumor VEGF-A levels, however, have not been found to predict the survival benefit of bevacizumab in retrospective subset analyses (24, (26) (27) (28) .
Plasma markers offer a number of advantages over tissue-based markers, including the ability to perform continuous, noninvasive assessments over time, which may be more relevant to the metastatic tumor being treated than to the tissue-based measurements of VEGF-A in archival primary tumors. Earlier research failed to demonstrate a difference in the survival benefit afforded by bevacizumab in subsets of patients with different circulating levels of VEGF-A (11, 29) . Unfortunately, interpretation of these initial studies is limited as they describe small cohorts or single clinical trials that lack statistical power in retrospective subset analyses.
To assess the role of VEGF-A in predicting benefit from bevacizumab in as rigorous a utility of circulating VEGF-A levels in these studies, we also examined the relationship between plasma and tumor VEGF-A levels. This is the first report of a multi-study analysis of plasma VEGF-A as a biomarker of response to bevacizumab treatment.
PATIENTS AND METHODS

Study Design
These retrospective analyses meet the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria. The sample size was chosen to maximize statistical power in an exploratory fashion, not to detect a prespecified effect size. Table 1 .
Sample Collection
In all studies, patient consent was obtained prior to sample collection, and plasma was collected from patients at baseline. Plasma was also collected from 40 healthy donors who consented to exploratory analysis. After collection, 2 to 3 mL of citrated plasma was stored at −80˚C. These samples were shipped between sites on dry ice. Upon aliquoting, several hundred microliters (depending on the recipient) were transferred into 96-well plates or microtube racks. These aliquots were stored at −80˚C until distribution to different sites on dry ice. Formalin-fixed paraffin-embedded archival tissue samples and matched baseline plasma samples were obtained from patients enrolled in the AVF2107 (12, 21) and AVF2938 (31) studies.
Assays
All experiments and analyses were performed at Genentech where laboratory scientists were blinded to treatment group and clinical outcome. The plasma VEGF-A enzymelinked immunosorbent assay (ELISA) assay GEN.038 was designed to recognize all major isoforms of VEGF-A, including VEGF 121 , VEGF 165 , and VEGF 110 (the plasmincleaved product of VEGF 165 ) with equivalent sensitivity (Supplemental Fig. 1 immunoglobulin G) were added to the plate and incubated for 1.5 to 2 hours at 37°C.
The plates were washed with buffer containing PBS, 0.05% polysorbate 20. Bound VEGF-A was detected with biotinylated A4.6.1, followed by streptavidin-conjugated β-galactosidase (Merck KGaA; Darmstadt, Germany). Fluorescence was read at 360 nm for excitation absorbance and 450 nm for emission. The lower and upper limits of quantitation in the assay were 2.5 and 88.9 pg/mL, respectively. The quantifiable range in a sample is 12.5 to 889 pg/mL. The percent recovery of VEGF 165 added to citrated plasma from 6 patients with mCRC ranged from 80% to 108%. Inter-assay coefficients of variability (CVs) ranged from 17% to 21%, and intra-assay CVs ranged from 7% to Tissue microarrays to measure VEGF-A mRNA expression by in situ hybridization (ISH) were assembled as described previously (32) . For tissue microarrays measuring VEGF-A mRNA expression, riboprobe synthesis, hybridization, development, and analysis were carried out as described previously (24, 33) . Hybridization of antisense β-actin riboprobes was confirmed in all tissues. Sense riboprobes were employed as negative controls for hybridization specificity. Tissue microarray cores were scored semiquantitatively on a scale of 0 (no expression) to 3 (very strong signal), according to Microarray data for tumor and matched normal breast, lung, colon, and kidney tissue VEGF-A mRNA expression were obtained from GeneLogic (Gaithersburg, MD).
Probeset 210512_s_at was chosen to represent VEGF-A expression.
Statistical Analyses
Patients with a baseline plasma sample and a valid total plasma VEGF-A result were included in the biomarker analysis population. Patients with missing data were excluded from analyses. Patient baseline characteristics were summarized in the biomarker population and compared with all patients enrolled in each study. The interaction between baseline plasma VEGF-A levels and PFS or OS was analyzed to determine whether it was a prognostic or predictive relationship: PFS was defined as the time from randomization until disease progression or death from any cause, while OS was defined as the time from randomization until death from any cause.
Continuous data were categorized into high vs. low plasma VEGF-A levels by using a median cut point. To identify the prognostic value of baseline VEGF-A level, a stratified log-rank test was used to assess differences in the distributions of PFS and OS in the lower and upper median in placebo-treated patients. A P value of <0.05 was considered to be statistically significant. Median PFS and OS values, together with 95% confidence intervals, for patients with pretreatment VEGF-A levels were estimated according to median VEGF-A level using the Kaplan-Meier method. In the predictive analysis, median PFS and OS values were estimated using the Kaplan-Meier method; hazard 
ratios (HRs) and 95% confidence intervals for PFS and OS for bevacizumab-and placebo-treated patients in the low-plasma and high-plasma VEGF-A groups were produced by a multivariable Cox regression model adjusted for baseline stratification factors that were used for randomization.
RESULTS
Patient Demographics and Sampling
Plasma samples from 384 patients (42%) in AVF2107, 166 patients (19%) in E4599, 882 patients (85%) in AVAiL, and 384 patients (59%) in AVOREN were available for analysis. Ninety-seven matched tumor samples from AVF2107 and 35 from AVF2938
were also available for ISH. In each of the randomized phase III studies, the demographic, clinical, and pathologic characteristics of sampled patient groups were similar to those found in the population with and without available VEGF-A samples (Supplemental Table 1 ).
Plasma and Tissue VEGF-A Levels
Plasma samples from patients in the 4 phase III studies were analyzed for total circulating VEGF-A levels. The observed distribution of patients by circulating VEGF-A level was similar across all 3 tumor types (Fig. 1) , with at least 34% of patients in the mCRC, NSCLC, and mRCC studies having a VEGF-A level ≥50 pg/mL. Median circulating VEGF-A concentrations were 44 pg/mL, 36 pg/mL, 45 pg/mL, and 55 pg/mL in AVF2107, E4599, AVAiL, and AVOREN, respectively. By contrast, median circulating VEGF-A concentration in 40 healthy subjects was below the limit of quantitation (12. 
pg/mL). The VEGF concentrations in the 17 subjects with detectable VEGF levels did not exceed 49 pg/mL.
There was no evidence of an association between circulating and tumor VEGF-A levels according to matched plasma and tumor samples from AVF2107 and AVF2938 (Fig. 2) .
A detailed overview of this assay and its scoring was published elsewhere (24) .
Association of Circulating VEGF-A Levels With Patient Outcome
To assess the prognostic significance of circulating VEGF-A levels, low and high circulating VEGF-A subsets by median were analyzed for placebo-treated patients with available samples in each of the 4 phase III trials (Table 2) . Point estimates for median OS showed a significant prognostic effect for circulating VEGF-A in all but 1 of the trials.
By contrast, the prognostic effect of circulating VEGF-A levels on PFS did not reach statistical significance in any of the trials.
The predictive value of VEGF-A was assessed by calculating HRs for PFS and OS, according to baseline total circulating VEGF-A level (as defined at the median) and treatment arm (see Fig. 3 ). For this analysis, the low-dose (7.5 mg/kg every 3 weeks In support of these findings, recent data using a novel VEGF-A ELISA assay with higher sensitivity to shorter, more soluble VEGF-A isoforms, including VEGF 110 and VEGF 121 , also identified that baseline plasma VEGF-A had prognostic, but not predictive, value in mCRC, NSCLC, and mRCC (35) . By contrast, this assay was predictive in determining bevacizumab response in metastatic breast cancer, gastric cancer, and pancreatic cancer (35, 36) . High baseline plasma VEGF-A was found to correlate with trends toward improved OS and PFS in these latter tumor types. There are several important differences, however, in the conduct of these analyses. In addition to the tumor types evaluated, samples in breast, gastric, and pancreatic cancers used EDTA plasma rather than citrated plasma (35) . We used citrated plasma in the current analysis because this method of anticoagulation has minimal effect on platelet activation. Moreover, the low dynamic range of plasma VEGF-A levels in healthy controls (<12.5-49 pg/mL) suggests that the impact of uncontrolled platelet activation would be minimal in cancer patients (<12.5->900 pg/mL) (see Fig. 1 ). One caveat is that the number of platelets and levels of VEGF isoforms in platelets at baseline in cancer patients may be different from healthy donors. It is unclear whether isoforms of VEGF-A are differentially represented in citrated versus EDTA plasma or whether platelets release different isoforms that affect treatment efficacy in some indications, thus confounding comparisons between these studies. To date, data are not available to determine if circulating VEGF-A using EDTA plasma is predictive in mCRC, NSCLC, and mRCC; however, the number of patients evaluated and the determination of prognostic significance for circulating VEGF-A in these tumor types lend credence to the validity of the current findings. 
